<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Conceptus Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/conceptus-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HOLX) Hologic Launches C-View Software</title>
		<link>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723</link>
		<comments>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:47:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87723</guid>
		<description><![CDATA[Hologic (HOLX), a leading player in the field of women’s health, has released its C-View synthesized 2D image reconstruction algorithm. This eliminates the requirement of a conventional 2D mammogram as a part of a 3D mammography (tomosynthesis breast cancer screening). The C-View software creates a 2D image from a single tomosynthesis, thus doing away with the need for additional 2D exposures. Hologic will feature the new algorithm along with its Selenia Dimensions breast tomosynthesis system at the annual meeting of the Radiological Society of North America (RSNA), currently underway in Chicago. Earlier this year, Hologic received approval from the US Food and Drug Administration (FDA) for its Selenia Dimensions 3D digital mammography tomosynthesis system. The device is capable of producing both 3D and conventional 2D images that can be used ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AIG) Company News for May 12, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928</link>
		<comments>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928#comments</comments>
		<pubDate>Thu, 12 May 2011 15:10:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Ener1 Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Harvest Natural Resources Inc]]></category>
		<category><![CDATA[HEV]]></category>
		<category><![CDATA[HNR]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Northwest Pipe Company]]></category>
		<category><![CDATA[NWPX]]></category>
		<category><![CDATA[Scientific Games Corporation]]></category>
		<category><![CDATA[SGMS]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73928</guid>
		<description><![CDATA[•    Shares of Ener1, Inc. (NASDAQ:HEV) plunged by 27.35%, after the company reported a large first-quarter net loss this week. Ener1 Inc. was also downgraded by Wunderlich Securities from &#8220;Hold&#8221; to &#8220;Sell&#8221; and its price target was reduced from $3.50 to $1.00 •    Global and federal government insurer American International Group, Inc (NYSE:AIG) revealed in a regulatory filing that they would sell 300 million shares to the public •    Strong earnings results that grew more than three times in the first quarter helped share prices of the pipeline maker Northwest Pipe Co (NASDAQ:NWPX) surge 6.40% to close at $24.45 •    Internet portal Yahoo! Inc (NASDAQ:YHOO) reported that Alibaba Group has transferred ownership of its online payments business to an entity controlled by the CEO of Alibaba. Reacting to the news, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Earnings Report Shows Strong Growth</title>
		<link>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177</link>
		<comments>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177#comments</comments>
		<pubDate>Wed, 04 May 2011 16:37:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73177</guid>
		<description><![CDATA[Hologic (HOLX) reported an adjusted EPS of 30 cents during the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues were $438.7 million, an increase of 4.9% compared to the prior-year quarter and higher than the Zacks Consensus Estimate of $433 million. Hologic operates through four segments ? Breast Health, Diagnostics, GYN (Gynecology) Surgical and Skeletal Health ? which contributed 47%, 32%, 16% and 5%, respectively to the total revenue during the quarter. Barring Diagnostics revenue, which declined 1.2% to $138.2 million during the quarter, the other three segments recorded a robust growth of 8.7% ($205.9 million), 6.5% ($71.5 million) and 7.1% ($23.1 million), respectively. The strong growth witnessed by Breast Health was primarily driven by the rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPTS) Conceptus Inc. &#8211; 29% Increase in Sales</title>
		<link>http://www.stockbloghub.com/2009/12/02/cpts-conceptus-inc-29-increase-in-sales/21708</link>
		<comments>http://www.stockbloghub.com/2009/12/02/cpts-conceptus-inc-29-increase-in-sales/21708#comments</comments>
		<pubDate>Wed, 02 Dec 2009 15:03:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21708</guid>
		<description><![CDATA[Conceptus, Inc (CPTS) is poised for explosive growth over the next couple years and just reported another earnings surprise. Company Description Conceptus specializes in women&#8217;s healthcare and developed the Essure procedure. The trademarked procedure is an alternative form of birth control that does not use hormones, drugs, or surgery. The body naturally forms a barrier around inserts and prevents conception. Topped Guidance On Oct 21 Conceptus reported third-quarter results that included a 29% increase in sales, to $34.2 million. Net income came in at just over $6 million, adjusted to 24 cents per share. The Zacks Consensus Estimate was just 9 cents, making it the third consecutive earnings surprise. Given the strong quarter, the company also raised guidance for the next quarter. Estimates Pop Following the report the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/cpts-conceptus-inc-29-increase-in-sales/21708/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CPTS) Conceptus, Inc. &#8211; Earnings Report Crushes Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/28/cpts-conceptus-inc-earnings-report-crushes-estimates/19016</link>
		<comments>http://www.stockbloghub.com/2009/10/28/cpts-conceptus-inc-earnings-report-crushes-estimates/19016#comments</comments>
		<pubDate>Wed, 28 Oct 2009 22:27:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19016</guid>
		<description><![CDATA[Conceptus, Inc. (CPTS) crushed analyst estimates after a very beneficial acquisition. Company Description Concept us makes a proprietary birth control product for women called Essure. The Essure procedure is permanent, done with out any incisions, and right in the doctor&#8217;s office. The procedure is available in the Americas, Europe, Australia, and the Middle East. Crushed Estimates The company reported third-quarter results on Oct 21st that included a 29% increase in sales, to $34.2 million. Conceptus was expecting between $32 and $33.5 million in sales. Net income more than tripled to $6.2 million, up from $2.0 million in the same period last year. This equated to an adjusted EPS pf 24 cents, well above the 9 cents analysts were expecting. Analysts React Since Conceptus reported its third consecutive earnings surprise, 8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/cpts-conceptus-inc-earnings-report-crushes-estimates/19016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems Sells Ovion Technology</title>
		<link>http://www.stockbloghub.com/2009/10/12/ammd-american-medical-systems-sells-ovion-technology/17372</link>
		<comments>http://www.stockbloghub.com/2009/10/12/ammd-american-medical-systems-sells-ovion-technology/17372#comments</comments>
		<pubDate>Mon, 12 Oct 2009 17:11:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17372</guid>
		<description><![CDATA[American Medical Systems (AMMD) recently announced that it has agreed to sell its female sterilization assets and technology to Conceptus Inc. (CPTS). Under the $23.6 million cash deal, Conceptus acquired all patents and intellectual property associated with the Ovion business, which was acquired by American Medical Systems in July 2005. American Medical Systems acquired Ovion Inc. to further broaden its gynecology franchise. Ovion, a pre-commercialization company, developed an office-based technology for the delivery of a permanent birth control solution for women. Conceptus intends to make use of the Ovion technology to develop future versions of its Essure permanent female contraceptive. Essure, a non-incisional permanent birth control method, received approval from the U.S. Food and Drug Administration (FDA) in 2002. Under the terms of the present agreement, Conceptus will not be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/12/ammd-american-medical-systems-sells-ovion-technology/17372/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

